Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,012
datasets available to search
ShareScore release 0.9.0
Dataset results
2,012 results for “Kinase”
Supplementary material 1 from: Yaseen Y, Kubba A, Shihab W, Tahtamouni L (2022) Synthesis, docking study, and structure-activity relationship of novel niflumic acid derivatives acting as anticancer agents by inhibiting VEGFR or EGFR tyrosine kinase activities. Pharmacia 69(3): 595-614. https://doi.org/10.3897/pharmacia.69.e86504
Figures S1, S2, Tables S1, S2
Kinase-Bench
Open the record for dataset details and reuse information.
Atomistic Predictions and Network-Based Allosteric Analysis of Conformational Ensembles for the State-Switching ABL Kinase Mutants Using Combination of Alanine Sequence Scanning and Shallow Subsampling in AlphaFold2
Open the record for dataset details and reuse information.
Dataset for the ARON-1 trial, paper "Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell CarcinomaTreated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from theARON-1 Retrospective Study)"
<p>Dataset for the ARON-1 trial</p>
MassSpectrometry Dataset to "Mitochondrial Creatine Kinase 2 (Ckmt2) as a Plasma-Based Biomarker for Evaluating Reperfusion Injury in Acute Myocar-dial Infarction"
Open the record for dataset details and reuse information.
Data from: Systems analysis of adaptive responses to MAP Kinase pathway blockade in BRAF mutant melanoma
Fifty percent of cutaneous melanomas are driven by activated BRAFV600E, but tumors treated with RAF inhibitors, even when they respond dramatically, rapidly adapt and develop resistance. Thus, there is a pressing need to identify the major mechanisms of intrinsic and adaptive resistance and develop drug combinations that target these resistance mechanisms. In a combinatorial drug screen on a panel of 12 treatment-naïve BRAFV600E mutant melanoma cell lines of varying levels of resistance to mitogen-activated protein kinase (MAPK) pathway inhibition, we identified the combination of PLX4720, a targeted inhibitor of mutated BRaf, and lapatinib, an inhibitor of the ErbB family of receptor tyrosine kinases, as synergistically cytotoxic in the subset of cell lines that displayed the most resistance to PLX4720. To identify potential mechanisms of resistance to PLX4720 treatment and synergy with lapatinib treatment, we performed a multi-platform functional genomics analysis to profile the genome as well as the transcriptional and proteomic responses of these cell lines to treatment with PLX4720. We found modest levels of resistance correlated with the zygosity of the BRAF V600E allele and receptor tyrosine kinase (RTK) mutational status. Layered over base-line resistance was substantial upregulation of many ErbB pathway genes in response to BRaf inhibition, thus generating the vulnerability to combination with lapatinib. The transcriptional responses of ErbB pathway genes are associated with a number of transcription factors, including ETS2 and its associated cofactors that represent a convergent regulatory mechanism conferring synergistic drug susceptibility in the context of diverse mutational landscapes.
Dataset (IX) related to publication: Decisive Role of Water and Protein Dynamics in Residence Time of p38a MAP Kinase Inhibitors
<p>Well-tempered metadynamics simulation data of compounds <strong>1 </strong>and<strong> 2</strong> of the related to the publication Pantsar et al.: <em>Decisive Role of Water and Protein Dynamics in Residence Time of p38a MAP Kinase Inhibitors.</em></p> <p>Individual .zip files contain raw-desmond trajectories (-out.cms files and trj-files).</p> <p>All datasets related to this publication:</p> <p><a href="https://doi.org/10.5281/zenodo.4568113">https://doi.org/10.5281/zenodo.4568113</a>(compound <strong>1</strong>; dataset: I)</p> <p><a href="https://doi.org/10.5281/zenodo.4572444">https://doi.org/10.5281/zenodo.4572444</a> (compound <strong>1</strong>; dataset: II)</p> <p><a href="https://doi.org/10.5281/zenodo.4561797">https://doi.org/10.5281/zenodo.4561797</a>(compound <strong>2</strong>; dataset: III)</p> <p><a href="https://doi.org/10.5281/zenodo.4563896">https://doi.org/10.5281/zenodo.4563896</a> (compound <strong>2</strong>; dataset: IV)</p> <p><a href="https://doi.org/10.5281/zenodo.5563359">https://doi.org/10.5281/zenodo.5563359</a> (<strong>SB203580</strong>; dataset: V)</p> <p><a href="https://doi.org/10.5281/zenodo.5563655">https://doi.org/10.5281/zenodo.5563655</a> (<strong>SB203580</strong>; dataset: VI)</p> <p><a href="https://doi.org/10.5281/zenodo.5564118%20">https://doi.org/10.5281/zenodo.5564118 </a>(compound <strong>1</strong> simulated in compound <strong>2</strong> metastable state <strong>2-<em>S</em><sub>3</sub></strong>; dataset: VII)</p> <p><a href="https://doi.org/10.5281/zenodo.5564208%20">https://doi.org/10.5281/zenodo.5564208 </a>(compound <strong>1</strong> simulated in compound <strong>2</strong> metastable state <strong>2-<em>S</em><sub>3</sub></strong>; dataset: VIII)</p> <p><a href="https://doi.org/10.5281/zenodo.5564586">https://doi.org/10.5281/zenodo.5564586</a> (well-tempered metadynamics simulations of compounds <strong>1</strong> and <strong>2</strong>; dataset: IX)</p> <p><a href="https://doi.org/10.5281/zenodo.5570882">https://doi.org/10.5281/zenodo.5570882</a> (well-tempered metadynamics simulations of compounds <strong>1</strong> and <strong>2</strong>; dataset: X)</p> <p><a href="https://doi.org/10.5281/zenodo.5571352">https://doi.org/10.5281/zenodo.5571352</a> (well-tempered metadynamics simulations of compounds <strong>1</strong> and <strong>2</strong>; dataset: XI)</p> <p>The datasets include original Desmond raw-trajectories (datasets I–VIII), PDB-coordinates for the energy minimized metastable state derived structures (datasets II, IV and VI) and raw-trajectories of the well-tempered metadynamics simulations (dataset IX–XI).</p>
Dataset (X) related to publication: Decisive Role of Water and Protein Dynamics in Residence Time of p38a MAP Kinase Inhibitors
<p>Well-tempered metadynamics simulation data of compounds <strong>1 </strong>and<strong> 2</strong> of the related to the publication Pantsar et al.: <em>Decisive Role of Water and Protein Dynamics in Residence Time of p38a MAP Kinase Inhibitors.</em></p> <p>Individual .zip files contain raw-desmond trajectories (-out.cms files and trj-files).</p> <p>All datasets related to this publication:</p> <p><a href="https://doi.org/10.5281/zenodo.4568113">https://doi.org/10.5281/zenodo.4568113</a>(compound <strong>1</strong>; dataset: I)</p> <p><a href="https://doi.org/10.5281/zenodo.4572444">https://doi.org/10.5281/zenodo.4572444</a> (compound <strong>1</strong>; dataset: II)</p> <p><a href="https://doi.org/10.5281/zenodo.4561797">https://doi.org/10.5281/zenodo.4561797</a>(compound <strong>2</strong>; dataset: III)</p> <p><a href="https://doi.org/10.5281/zenodo.4563896">https://doi.org/10.5281/zenodo.4563896</a> (compound <strong>2</strong>; dataset: IV)</p> <p><a href="https://doi.org/10.5281/zenodo.5563359">https://doi.org/10.5281/zenodo.5563359</a> (<strong>SB203580</strong>; dataset: V)</p> <p><a href="https://doi.org/10.5281/zenodo.5563655">https://doi.org/10.5281/zenodo.5563655</a> (<strong>SB203580</strong>; dataset: VI)</p> <p><a href="https://doi.org/10.5281/zenodo.5564118%20">https://doi.org/10.5281/zenodo.5564118 </a>(compound <strong>1</strong> simulated in compound <strong>2</strong> metastable state <strong>2-<em>S</em><sub>3</sub></strong>; dataset: VII)</p> <p><a href="https://doi.org/10.5281/zenodo.5564208%20">https://doi.org/10.5281/zenodo.5564208 </a>(compound <strong>1</strong> simulated in compound <strong>2</strong> metastable state <strong>2-<em>S</em><sub>3</sub></strong>; dataset: VIII)</p> <p><a href="https://doi.org/10.5281/zenodo.5564586">https://doi.org/10.5281/zenodo.5564586</a> (well-tempered metadynamics simulations of compounds <strong>1</strong> and <strong>2</strong>; dataset: IX)</p> <p><a href="https://doi.org/10.5281/zenodo.5570882">https://doi.org/10.5281/zenodo.5570882</a> (well-tempered metadynamics simulations of compounds <strong>1</strong> and <strong>2</strong>; dataset: X)</p> <p><a href="https://doi.org/10.5281/zenodo.5571352">https://doi.org/10.5281/zenodo.5571352</a> (well-tempered metadynamics simulations of compounds <strong>1</strong> and <strong>2</strong>; dataset: XI)</p> <p>The datasets include original Desmond raw-trajectories (datasets I–VIII), PDB-coordinates for the energy minimized metastable state derived structures (datasets II, IV and VI) and raw-trajectories of the well-tempered metadynamics simulations (dataset IX–XI).</p>
CATH-KinFams: CATH Protein Kinase classification alignments and Hidden Markov Models
<p>CATH KinFams are protein kinase domain families classified according to functional similarity based on SDP. In this deposition we make available 2,210 KinFams sequence alignments alongside Hidden Markov Models built from them to be used with HMMER3.</p> <p>A concatenated library 'kinases_4.3-FF-seed.hmm' is also available to scan against the whole KinFams dataset.</p> <p>The Zenodo deposition contains:</p> <p>kinfams-cath-4.3-seed-alignments.tar.gz - KinFams FASTA file alignments with headers 'UniProt_ID/start-stop' i.e. A8XMX4/281-587</p> <p>kinfams-cath-4.3-seed-hmms.tar.gz - HMMs for each individual KinFam and concatenated in a HMM library.</p> <p>kinfams-cath-4.3-seed-mda-strings - Multi-Domain-Architecture string assignment for each sequence in the KinFams dataset.</p> <p>human_kinfams_af2_models_cif.tar.gz - Chopped mmCIF files containing Human Kinases AlphaFold2 Models.</p>
Dataset for the Tyrosine-protein kinase SYK antibody screening study
<p>This project contains the following underlying data included in a study aiming at characterizing antibodies for Tyrosine-protein kinase SYK. The study is available on Zenodo (https://doi.org/10.5281/zenodo.6566940).</p>
Fig. 5 in Mutagenesis of a Lotus japonicus GSK3β/Shaggy-like kinase reveals functionally conserved regulatory residues
Fig. 5. The enzymatic activity of native LjSK1. The inset shows the Lineweaver- Burk plot.
ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor
ClinicalTrials.gov study NCT04216563. IPD Sharing: Not stated. Countries: 1. Publications: 0.
SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes
ClinicalTrials.gov study NCT02644122. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon
ClinicalTrials.gov study NCT00498615. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Sorafenib In Relapse of FMS-like Tyrosine Kinase 3 (FLT3)-Internal Tandem Duplication (ITD) AML Trial
ClinicalTrials.gov study NCT02867891. IPD Sharing: NO. Countries: 0. Publications: 2.
Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy
ClinicalTrials.gov study NCT01428635. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Analysis of Cellular Kinases and Aging in PBMCs and Colorectal Tissue
ClinicalTrials.gov study NCT06132386. IPD Sharing: NO. Countries: 1. Publications: 0.
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
ClinicalTrials.gov study NCT02019693. IPD Sharing: YES. Countries: 1. Publications: 0.
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
ClinicalTrials.gov study NCT00639002. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Evaluation of Lithium as a Glycogen-Synthase-Kinase-3 (GSK-3) Inhibitor in Mild Cognitive Impairment
ClinicalTrials.gov study NCT02601859. IPD Sharing: Not stated. Countries: 0. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.